Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | GALR3 | O60755 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.39 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11787514 | 0.81 | ALDH1A1 (0.50) | CYP3A4MEN1KMT2ATSHRL3MBTL1 | |
| SCHEMBL4623730 | 0.79 | SMN1; SMN2 (0.49) | SMN1; SMN2CYP3A4CYP19A1MEN1KMT2A | |
| SCHEMBL7590710 | 0.78 | CYP19A1 (0.50) | SMN1; SMN2CYP3A4CYP19A1MEN1KMT2A | |
| SCHEMBL8250738 | 0.77 | CYP19A1 (0.54) | SMN1; SMN2CYP3A4CYP19A1MEN1KMT2A | |
| SCHEMBL11027636 | 0.75 | KMT2A (0.40) | SMN1; SMN2CYP3A4CYP19A1MEN1KMT2A | |
| SCHEMBL11027189 | 0.75 | CYP3A4 (0.38) | SMN1; SMN2CYP3A4CYP19A1MEN1KMT2A | |
| Hydrogen Peroxide SCHEMBL11574430 | 0.74 | KMT2A (0.47) | SMN1; SMN2CYP3A4CYP19A1MEN1KMT2A | |
| SCHEMBL5495729 | 0.74 | CYP19A1 (0.50) | SMN1; SMN2CYP3A4CYP19A1MEN1KMT2A | |
| SCHEMBL11213892 | 0.74 | CYP19A1 (0.50) | SMN1; SMN2CYP3A4CYP19A1MEN1KMT2A | |
| SCHEMBL7696997 | 0.74 | CYP19A1 (0.50) | SMN1; SMN2CYP3A4CYP19A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120064002-A1 | Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic Acid and Derivatives Thereof, Process for their Production and Use for the Production of Pharmaceutical Agents | LEHMANN LUTZ (DE) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064002-A1 | Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic Acid and Derivatives Thereof, Process for their Production and Use for the Production of Pharmaceutical Agents | CYP4B1, CYP2B6, UGT2B7 | SMN1; SMN2 2135/4885CYP3A4 15/4885CYP19A1 450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.